143 related articles for article (PubMed ID: 13679638)
1. Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer.
Shimizu M; Yoshimoto T; Matsuzawa A; Takeda Y
Mol Biotechnol; 2003 Sep; 25(1):79-87. PubMed ID: 13679638
[TBL] [Abstract][Full Text] [Related]
2. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
[TBL] [Abstract][Full Text] [Related]
3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
4. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo.
Shimizu M; Yoshimoto T; Nagata S; Matsuzawa A
Biochem Biophys Res Commun; 1996 Nov; 228(2):375-9. PubMed ID: 8920922
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells.
Shimizu M; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
Cancer Immunol Immunother; 1998 Nov; 47(3):143-8. PubMed ID: 9829839
[TBL] [Abstract][Full Text] [Related]
6. Frequency and resistance of CD95 (Fas/Apo-1) gene-transfected tumor cells to CD95-mediated apoptosis by the elimination and methylation of integrated DNA.
Shimizu M; Yoshimoto T; Sato M; Matsuzawa A; Takeda Y
Int J Cancer; 2006 Aug; 119(3):585-92. PubMed ID: 16506211
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction.
Riffkin CD; Gray AZ; Hawkins CJ; Chow CW; Ashley DM
Neuro Oncol; 2001 Oct; 3(4):229-40. PubMed ID: 11584892
[TBL] [Abstract][Full Text] [Related]
8. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
9. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase.
Wei SJ; Chao Y; Shih YL; Yang DM; Hung YM; Yang WK
Gene Ther; 1999 Mar; 6(3):420-31. PubMed ID: 10435092
[TBL] [Abstract][Full Text] [Related]
11. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
12. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
Imai T; Adachi S; Nishijo K; Ohgushi M; Okada M; Yasumi T; Watanabe K; Nishikomori R; Nakayama T; Yonehara S; Toguchida J; Nakahata T
Oncogene; 2003 Dec; 22(58):9231-42. PubMed ID: 14647441
[TBL] [Abstract][Full Text] [Related]
13. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
14. Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium.
Hamann KJ; Dorscheid DR; Ko FD; Conforti AE; Sperling AI; Rabe KF; White SR
Am J Respir Cell Mol Biol; 1998 Oct; 19(4):537-42. PubMed ID: 9761749
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
16. Immunological and pathological consequences of mutations in both Fas and Fas ligand.
Weintraub JP; Godfrey V; Wolthusen PA; Cheek RL; Eisenberg RA; Cohen PL
Cell Immunol; 1998 May; 186(1):8-17. PubMed ID: 9637760
[TBL] [Abstract][Full Text] [Related]
17. Roles of Fas and Fas ligand during mammary gland remodeling.
Song J; Sapi E; Brown W; Nilsen J; Tartaro K; Kacinski BM; Craft J; Naftolin F; Mor G
J Clin Invest; 2000 Nov; 106(10):1209-20. PubMed ID: 11086022
[TBL] [Abstract][Full Text] [Related]
18. Thymocyte apoptosis by T-2 toxin in vivo in mice is independent of Fas/Fas ligand system.
Murshedul AM; Nagase M; Yoshizawa T; Sakato N
Biosci Biotechnol Biochem; 2000 Jan; 64(1):210-3. PubMed ID: 10766511
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
Müller M; Strand S; Hug H; Heinemann EM; Walczak H; Hofmann WJ; Stremmel W; Krammer PH; Galle PR
J Clin Invest; 1997 Feb; 99(3):403-13. PubMed ID: 9022073
[TBL] [Abstract][Full Text] [Related]
20. Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor.
Shimizu M; Yoshimoto T; Sato M; Morimoto J; Matsuzawa A; Takeda Y
Int J Cancer; 2005 May; 114(6):926-35. PubMed ID: 15645421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
